Attovia Therapeutics (ATTO) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on next-generation biotherapeutics for immune-mediated diseases using its proprietary ATTOBODY platform.

• Lead candidates target validated pathways in chronic pruritic and inflammatory diseases, including atopic dermatitis, chronic pruritus, and inflammatory bowel disease.

• All product candidates are internally discovered using the in-licensed ATTOBODY biparatopic biologics platform from Alamar Biosciences.

• Pipeline includes ATTO-1310 (anti-IL-31, Phase 1), ATTO-2306 (bispecific anti-IL-13/IL-31, IND-enabling), and ATTO-1091 (trispecific anti-TL1A/IL-23/integrin a4β7, IND-enabling).

• Strategy emphasizes precision design, infrequent dosing, and expansion into multispecific and conditional “AND” gate biologics.

Financial performance and metrics

• No product revenue to date; revenue of $1.4 million in 2025 from a collaboration agreement.

• Net losses: $39.8 million (2024), $60.6 million (2025), $18.7 million (Q1 2026); accumulated deficit of $129.7 million as of March 31, 2026.

• Cash, cash equivalents, and marketable securities of $132.6 million as of March 31, 2026.

• Research and development expenses increased to $54.2 million in 2025, reflecting pipeline advancement.

• Pro forma net loss per share for 2025: $(2.37); pro forma as adjusted cash after IPO expected to be $399.0 million.

Use of proceeds and capital allocation

• Estimated net proceeds of $265.1 million from IPO (or $305.4 million if over-allotment is exercised), based on $17.00 per share.

• Proceeds to fund ATTO-1310 through Phase 2 ($110–130M), ATTO-2306 through Phase 2 ($60–80M), and advance ATTO-1091 and other pipeline programs.

• Remaining funds allocated to research, development, working capital, and general corporate purposes.

• Proceeds, together with existing cash, expected to fund operations into 2029.